comparemela.com
Home
Live Updates
Long-Term Follow-Up from CheckMate 214 in Advanced RCC : com
Long-Term Follow-Up from CheckMate 214 in Advanced RCC : com
Long-Term Follow-Up from CheckMate 214 in Advanced RCC
The expert panel discusses the 8-year follow-up data from CheckMate 214 looking at nivolumab plus ipilimumab in first-line advanced RCC and provide clinical insights on treatment decisions.
Related Keywords
,
Advanced Renal Cell Carcinoma ,
Term Follow Up ,
Renal Cell Carcinoma ,
Nrcc ,
Advanced Rcc ,
Checkmate 214 ,
Nivolumab ,
Ipilimumab ,
Metastatic Clear Cell Rcc ,
Ctla4 Inhibition ,
Ctla4 ,
Metastatic Clear Cell Renal Carcinoma ,